<mods:mods version="3.3" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-3.xsd" xmlns:mods="http://www.loc.gov/mods/v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><mods:titleInfo><mods:title>Therapy of Uncomplicated Falciparum  Malaria : A Randomized Trial Comparing Artesunate Plus Sulfadoxine-Pyrimethamine Versus Sulfadoxine-Pyrimethamine Alone in Irian Jaya, Indonesia</mods:title></mods:titleInfo><mods:name type="personal"><mods:namePart type="given">Emiliana</mods:namePart><mods:namePart type="family">Tjitra</mods:namePart><mods:role><mods:roleTerm type="text">author</mods:roleTerm></mods:role></mods:name><mods:abstract>Combining artesunate with existing antimalaria drugs may improve cure rates, delay emergence of resistance, and reduce transmisison. We performend a randomized comparative trial to quantify the effect  of adding artesunate to sulfadoxine-pyrimethamine in  the treatment of uncomplicated falciparum malaria in Indonesia.   Using a modified 1997 World Health Organization protocol for assessment of therapeutic efficacy of antimalaria drugs, 105 patients (stratified by age/ethnic group) were randomized: 53 received artesunate orally 4 mg/kg of body weight, a single daily dose for three days, plus sulfadoxine-pyrimethamine orally (1.25 mg of pyrimethamine/kg of body weight), a single dose on day 0 and 52 patients received sulfadoxine- pyrimethamine alone. Six from the combination group were withdrawn from analysis, as were six of the sulfadoxine-pyrimethamine group.   Treatment failure rates on day 14 were 0%in the artesunate plus sulfadoxine-pyrimethamine group and 8.7% in the sulfadoxine-pyrimethamine group (P=0.12). Treatment failure rates on day 28 were 4.4% and 15.2%, respectively (P=0.16). Relative risk of treatment failure at 28 day was 0.3 (95% confidence inteval [CI]=0.1&amp;#8211;1.3). Mean fever clearance time (1.3 versus 1.7 days) and mean parasite clearance time (1.4 versus 2.0 days) were both faster in the artesunate plus sulfadoxine-pyrimethamine group than in the  sulfadoxine-pyrimethamine group ( P=0.08 and P &lt; 0.0001, respectively). Only 20 (39.2) of 51 patients  treated with artesunate plus sulfadoxine-pyrimethamine were still parasitemic on day 1 compared with 45 (86,5%) of 52 patients treated with sulfadoxine-pyrimethamine alone  (P = 0.000001, relative risk [RR]=0.4,95% CI=0.3-0.6). Gametocyte carriage was  lower following artesunate plus sulfadoxine-pyrimethamine than following sulfadoxine-pyrimethamine  (RR=0.5, 95% CI=0.2-1.0 on day 7 and RR = 0.5, 95% CI=0.2-1.1 on day 14 ).   Mild diarrhea, rash and itching resolved without treatment. Combined artesunate plus sulfadoxine- pyrimethamine resulted in more rapid fever and parasites clearance, was well tolerated, reduced risk of treatment failure, and lowered gametocyte carriage.</mods:abstract><mods:classification authority="lcc">WC 680-950 Tropical and Parasitic Diseases</mods:classification><mods:originInfo><mods:dateIssued encoding="iso8601">2001</mods:dateIssued></mods:originInfo><mods:originInfo><mods:publisher>Pusat Penelitian dan Pengembangan Pemberantasan Penyakit</mods:publisher></mods:originInfo><mods:genre>Monograph</mods:genre></mods:mods>